NLRP1/NALP1 Antibody | 36-322

NLRP1/NALP1 Antibody | 36-322 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Synthetic peptide corresponding to aa 2-25 (A2GGAWGRLACYLEFLKKEELKEFQ25) at the N-terminus of human NLRP1/NALP1.

Research Area: Innate Immunity

Tested Application: WB

Application: Western Blot: (1:1, 000) .

Specificiy: Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: NACHT-, LRR- and PYD-containing Protein 1; NLRP1; Caspase Recruitment Domain-containing Protein 7; Death Effector Filament-forming Ced-4-like Apoptosis Protein; Nucleotide-binding Domain and Caspase Recruitment Domain

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.